Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Part of paid clinical trials in Tampa, Florida.
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Study ID
- NCT07047885
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Cutaneous T Cell Lymphoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ropeginterferon alfa-2b — DRUGWill be administered via subcutaneous injection once every 2 weeks
Study Details
This is a single-center, phase I/IB study to identify the recommended phase II dose of Ropeginterferon-alfa 2b (P1101) in patients with CTCL who have failed at least two prior lines of skin-directed therapy (Stage IA-IB) or have less than a complete response to phototherapy or extracorporeal photopheresis (ECP) or total skin electron beam therapy (TSET), or stable/progressive disease after at least two lines of topical therapy (Stage IIA-IIIB).
Key Dates
- Start date
- Aug 27, 2025
- Status verified
- Mar 2026
- Primary completion
- Jun 30, 2028
- Completion
- Jun 30, 2028
Study Design
- Enrollment
- 38 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Dose Level -2250 µg SQ every 2 weeks
- Experimental: Dose Level -1350 µg SQ every 2 weeks
- Experimental: Dose Level 1500 µg SQ every 2 weeks
- Experimental: Expansion ArmOnce the Recommended Phase 2 Dose (RP2D) is reached, an additional 20 participants will be treated at this dose for additional experience with safety and efficacy.
Primary Outcome Measure
Dose Limiting Toxicity [ Time Frame: 6 weeks ]
Central Contacts
- Richard Corona813-745-3465
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Moffitt Cancer Center | Tampa | Florida | 33612 | Yumeng Zhang, MD (PRINCIPAL_INVESTIGATOR) Celeste Bello, MD, MSPH (SUB_INVESTIGATOR) Julio Chavez, MD, MS (SUB_INVESTIGATOR) Sameh Gaballa, MD, MS (SUB_INVESTIGATOR) Leidy Isenalumhe, MD, MS (SUB_INVESTIGATOR) Bijal Shah, MD, MS (SUB_INVESTIGATOR) Lubomir Sokol, MD, PhD (SUB_INVESTIGATOR) |
Find similar trials in Tampa, FL
By research site
Related Studies
- Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCLPHASE3 · Recruiting · Soligenix · Phoenix, Arizona
- Characterization of the Microbiome in Cutaneous T Cell LymphomaRecruiting · Northwestern University · Chicago, Illinois
- Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With MogamulizumabRecruiting · Kyowa Kirin, Inc. · Milwaukee, Wisconsin
- A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell LymphomaRecruiting · Dana-Farber Cancer Institute · Boston, Massachusetts